01OverviewDefinition, clinical context and the essential points that orientate the chapter.
The ampulla of Vater joins biliary, pancreatic and duodenal epithelia. Tumours range from adenoma with dysplasia to invasive adenocarcinoma, neuroendocrine neoplasm and rarer lesions. Familial adenomatous polyposis markedly increases duodenal and ampullary adenoma risk. Sporadic lesions may present with jaundice, recurrent pancreatitis, iron-deficiency anaemia or an incidental enlarged papilla.
Biopsy establishes adenoma before papillectomy but has sampling limitations. A cancer focus may sit beneath an adenomatous surface, and recent sphincterotomy or inflammation can distort histology. Endoscopic appearance, multiple adequately directed biopsies, EUS depth, MRCP duct extension and cross-sectional staging must therefore agree. A negative superficial biopsy does not overrule a firm ulcerated obstructing lesion.
Endoscopic papillectomy preserves the organ in appropriately staged adenoma, but carries risks of pancreatitis, bleeding, cholangitis, perforation and later stenosis. Resectable invasive carcinoma usually requires pancreaticoduodenectomy in a fit patient for regional nodes and duct margins. Ampullary adenocarcinoma should be characterised as intestinal, pancreatobiliary or mixed phenotype alongside depth, margins and nodes; specialist oncology assessment must use the ampullary diagnosis and stage.
Key points
- Ampullary tumours arise where the bile and pancreatic ducts meet the duodenum; even a small lesion can cause early jaundice, cholangitis or pancreatitis.
- Obtain side-viewing duodenoscopy with directed biopsies, recognising that superficial samples can miss deeper carcinoma and that discordant malignant features need repeat or definitive assessment.
- ESGE recommends both EUS and MRCP for staging ampullary tumours because depth, nodes and intraductal extension determine treatment.
- Do not perform diagnostic papillectomy without proven adenoma. Offer endoscopic papillectomy for an adenoma without intraductal extension when en-bloc and safe resection are feasible.
- Aim for en-bloc resection up to about 20–30 mm so margins are interpretable; consider surgical treatment for lesions over 4 cm, technical infeasibility or intraductal involvement over 20 mm.
- Use prophylactic pancreatic-duct stenting after endoscopic papillectomy to reduce post-procedure pancreatitis risk, with unit protocols for retrieval or passage confirmation.
- After endoscopic or surgical ampullectomy, perform duodenoscopic inspection and scar biopsies within 3 months, at 6 and 12 months, then annually for at least 5 years.
02AetiologyUnderlying causes, associations and risk factors, with why each one matters.
Adenoma-carcinoma sequence
Dysplastic ampullary adenoma can acquire invasive capacity, supporting complete excision and histological surveillance of apparently benign lesions.
Familial adenomatous polyposis
APC-associated duodenal polyposis greatly increases ampullary adenoma risk and requires lifelong upper-gastrointestinal surveillance integrated with colorectal care.
Non-adenomatous tumours
Neuroendocrine, mesenchymal and metastatic lesions can enlarge the papilla and require different staging and treatment from epithelial adenoma.
03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.
- 1Shared outlet obstruction
Growth at the papilla narrows bile and pancreatic drainage, producing jaundice, ascending infection, recurrent pancreatitis or a double-duct appearance.
- 2Submucosal invasion
Carcinoma can extend beneath a benign-appearing adenomatous surface, explaining why shallow biopsies may under-stage the lesion.
- 3Intraductal extension
Tumour tracking proximally within bile or pancreatic ducts reduces the chance of complete endoscopic excision and changes the operation required.
- 4Lymphatic spread
Once invasive, ampullary carcinoma can reach peripancreatic nodes even when the mucosal component is relatively small.
04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.
Intermittent or progressive jaundice can occur while the ampullary primary remains small because it sits at the shared duct outlet.
Unexplained recurrent acute pancreatitis or simultaneous bile- and pancreatic-duct dilatation should prompt careful ampullary and pancreatic assessment.
A regular soft granular papillary lesion may be adenomatous, but histology and duct staging are required before endoscopic resection.
Ulceration, friability, firmness, non-lifting tissue, deep duct extension or suspicious nodes increase concern for carcinoma and surgical treatment.
Severe epigastric pain, tachycardia, melaena, fever or peritonism after papillectomy needs urgent assessment for pancreatitis, bleeding, cholangitis or perforation.
05InvestigationsWhat to request, why it matters and how to interpret it.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Side-viewing duodenoscopy with biopsyFirst step - Why
- Inspect papillary architecture and obtain histology before deciding on resection.
- Interpretation and limitations
- Correlate adenoma grade with appearance; repeat samples or surgical assessment when biopsy is negative or low-grade but the lesion is ulcerated, firm or obstructing.
- 02
Endoscopic ultrasound - Why
- Assess depth through the duodenal wall, duct involvement and suspicious regional nodes.
- Interpretation and limitations
- EUS helps separate mucosal adenoma from invasive disease but operator and lesion factors limit certainty; tissue or resection pathology remains decisive.
- 03
MRI with MRCP - Why
- Map bile-duct and pancreatic-duct calibre and measure intraductal extension without cannulation.
- Interpretation and limitations
- Duct extension changes endoscopic feasibility. MRCP complements rather than duplicates EUS by showing the full fluid-filled duct system.
- 04
Contrast CT chest, abdomen and pelvis - Why
- Stage suspected invasive carcinoma for vascular, nodal and distant disease.
- Interpretation and limitations
- A small ampullary primary may be subtle; duct dilatation can be more conspicuous. Resectability and metastases require specialist review.
- 05
Resection histology - Why
- Determine completeness, dysplasia grade, invasive focus, differentiation, lymphovascular invasion and ductal margins.
- Interpretation and limitations
- Unexpected invasive cancer, positive deep margin or high-risk histology after papillectomy triggers HPB surgical review rather than surveillance alone.
- 06
Liver tests and serum lipase - Why
- Quantify biliary obstruction and identify associated or post-procedure pancreatitis.
- Interpretation and limitations
- Falling bilirubin after relief verifies bile flow; lipase must be interpreted with pain and organ assessment rather than used alone to grade severity.
06Differential diagnosisRealistic alternatives and the features that help distinguish them.
Prolapsed duodenal tissue
Inflammatory or hyperplastic papillary change can mimic neoplasia during endoscopy and requires adequate targeted histological confirmation before treatment.
Distal cholangiocarcinoma
A lower bile-duct primary may extend to the ampulla; duct-centred imaging and definitive pathology establish its origin.
Pancreatic-head cancer
Both produce distal biliary obstruction and double-duct dilatation, but EUS and pancreatic-protocol imaging localise a pancreatic mass.
Duodenal adenoma
A non-ampullary lesion beside the papilla has different relationships to both duct orifices and a distinct endoscopic resection risk.
07ManagementImmediate care, first-line treatment, alternatives and escalation.
01Endoscopically resectable adenomaStage before papillectomyFirst stepBiopsies show ampullary adenoma; EUS finds no invasion or suspicious nodes and MRCP shows no intraductal extension.+
- 1Review size, morphology, antithrombotic management and procedural fitness in an experienced therapeutic endoscopy service.
- 2Perform en-bloc endoscopic papillectomy when feasible and place a prophylactic pancreatic-duct stent according to ESGE guidance. For the selected stent intended for planned retrieval, book the six-week endoscopy now; symptoms suggesting obstruction require earlier review.
- 3Retrieve the specimen intact and orient it for lateral and deep margins; monitor immediately for bleeding, perforation, cholangitis and pancreatitis.
- 4Resection histology confirms low-grade adenoma with clear margins. The unit has selected a pancreatic stent intended for planned retrieval; at the six-week post-papillectomy endoscopy it is still present and is removed uneventfully. Scar inspection and biopsy at three months show no residual adenoma, and the six- and twelve-month visits are booked.
02Suspected invasive carcinomaChoose oncological resectionA firm ulcerated papilla causes jaundice; EUS suggests muscular invasion and CT shows no distant metastasis.+
- 1Obtain adequate histology and complete staging without attempting piecemeal diagnostic papillectomy.
- 2Discuss resectability, operative fitness and biliary decompression need at the HPB MDT.
- 3Offer pancreaticoduodenectomy with regional nodal assessment when invasive carcinoma is resectable and the patient accepts treatment.
- 4Review final depth, nodes, margins and intestinal/pancreatobiliary phenotype at the ampullary HPB oncology meeting, then document the individual further-treatment discussion and surveillance plan.
03Residual or recurrent adenomaRe-stage the scarSurveillance biopsy at 6 months finds a small focus of adenoma at the papillectomy margin.+
- 1Review the original specimen margins and repeat careful side-viewing examination with biopsies.
- 2Repeat EUS or MRCP if duct extension or deeper recurrence is possible.
- 3Use an experienced endoscopic retreatment method only when residual disease remains superficial and technically safe.
- 4Confirm clearance histologically and return to a documented long-term duodenoscopic surveillance schedule.
08ComplicationsImportant consequences, why they occur and why they matter clinically.
Acute pancreatitis
Tumour or papillectomy-related oedema obstructs the pancreatic orifice, causing pain, enzyme rise and occasionally organ failure.
Ascending cholangitis
Impaired bile flow permits bacterial ascent and bacteraemia and may require urgent antimicrobial treatment with endoscopic decompression.
Papillectomy bleeding
Immediate or delayed haemorrhage can produce melaena, anaemia and haemodynamic compromise requiring resuscitation and repeat endoscopic haemostasis.
Residual adenoma
Positive or thermally indeterminate margins and microscopic scar recurrence justify scheduled duodenoscopy with biopsies for at least five years.
09Monitoring and follow-upTreatment response, safety checks and longer-term review.
- Observe after papillectomy for pain, vomiting, fever, haemodynamic change and gastrointestinal bleeding, with lipase and imaging guided by symptoms.
- Record the pancreatic-stent type and intended passage or retrieval strategy. In the ampullary guideline, the first post-papillectomy endoscopy is commonly at 4–8 weeks, within three months, and permits planned retrieval. Confirm the actual result; symptomatic obstruction needs earlier review. Keep this papillectomy context separate from the general ERCP short prophylactic-stent 5–10-day passage check.
- Inspect the papillectomy scar with duodenoscopy and biopsies within 3 months, then at 6 and 12 months, and annually for at least 5 years.
- After cancer resection, follow the specialist plan for nutrition, pancreatic insufficiency, diabetes, pathology-led oncology and recurrence imaging.
- In FAP, integrate the ampullary result with systematic duodenal surveillance and inherited-cancer care rather than treating the papilla in isolation.
10Special situationsVariants, exceptions and circumstances that change the usual approach.
Small lesions can obstruct early
Ampullary location explains why jaundice may appear before a large mass and can make disease resectable at presentation.
Biopsy can under-stage
Adenomatous surface tissue can conceal invasive cancer, so discordant firmness, ulceration or imaging must prompt deeper evaluation.
Two staging views are complementary
EUS examines wall layers and nodes, while MRCP maps intraductal extension across both duct systems.
En-bloc aids pathology
One intact specimen gives a more interpretable deep and lateral margin than fragmented thermal tissue.
Surveillance uses biopsies
Visual normality at a papillectomy scar does not exclude microscopic residual adenoma, so scheduled sampling is part of follow-up.
11Common pitfallsFrequent interpretation and management errors.
- 01
Removing an enlarged papilla without biopsy-proven adenoma turns diagnosis into a high-risk therapeutic procedure.
- 02
Calling superficial benign biopsy definitive despite ulceration or duct invasion can miss an underlying carcinoma.
- 03
Using EUS alone without MRCP can underappreciate longitudinal intraductal extension relevant to resection choice.
- 04
Forgetting prophylactic pancreatic-duct stenting after papillectomy increases avoidable post-procedure pancreatitis risk.
- 05
Ending follow-up after a clear early scar ignores late recurrence and the ESGE schedule of at least five years.